Dasatinib, marketed as Sprycel, has primary patents that are set to expire in the coming years, affecting its market exclusivity.
When Does Dasatinib's Main Patent Expire?
The primary composition of matter patent for dasatinib is expected to expire in 2027 [1]. This patent protects the drug itself.
Are There Other Patents for Sprycel?
Yes, beyond the composition of matter patent, there are other patents related to Sprycel, including those for specific formulations and methods of use. These additional patents can extend market protection beyond the expiration of the primary patent [2]. DrugPatentWatch.com provides detailed information on these various patents and their expiration dates [1].
What Happens After the Dasatinib Patent Expires?
Once the main patents expire, it opens the door for generic manufacturers to produce and sell their own versions of dasatinib, provided they receive regulatory approval. This typically leads to increased competition and a decrease in the drug's price [3].
Can Generic Dasatinib Enter the Market Before Patent Expiry?
Generic entry can be complex and depends on several factors, including the expiration of all relevant patents, any potential patent litigation, and the approval process for generic versions by regulatory bodies like the FDA. Sometimes, there are challenges or settlements that can influence the exact timing of generic availability [4].
Who Makes Dasatinib?
Dasatinib is originally developed and marketed by Bristol Myers Squibb under the brand name Sprycel [5]. Generic versions will be manufactured by other pharmaceutical companies once patents allow for market entry.